Page 57 - Aet News Today

Dr. Brian Clear, an addiction treatment physician and chief medical officer of Bicycle Health, believes that telemedicine is one way to improve access and reduce the inequities inherence in addiction treatment. The other is education.

Providers must abandon paternalism and treat patients like partners in the decision-making process when drawing up care plans, according to Chris Waugh, Sutter Health's chief design and innovation officer. Instead of prescribing a major lifestyle overhaul without considering a patient's unique life circumstances, providers should "recognize that it's about the tiny things and the accumulation of marginal gains,” he said.

Patient communications platform Artera teamed up with healthcare AI startup Hyro to launch a new chatbot-style assistant for providers’ websites. Using the information already available on the provider’s website, the chatbot can answer patients’ questions 24/7. Some sample questions include “What are the office hours for the radiology department?” and “Where do I park for my visit?”

Flexible, portable medical diagnostic devices are the future, augmenting equity and access to quality healthcare. That means designing for patients as well as caregivers, creating devices that are intuitive, easy to use, and easily adaptable to various environments.

Government funding plays a major role in the advancement of drugs, including monoclonal antibodies, which are extremely expensive to produce and can take months to develop.

Gilead Sciences is increasing its stake in partner Arcellx and expanding the cell therapy alliance the companies started in 2022. The deal expands the lead partnered program to more cancers and gives Gilead a chance at another Arcellx cell therapy candidate made with different technology.

New KFF focus groups revealed that some thought the process of renewing Medicaid coverage during the unwinding of the continuous enrollment provision was simple. Others, however, faced challenges with communication from state Medicaid agencies, and some weren't aware their coverage had been terminated.

Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy. Forge specializes in manufacturing AAV vectors used to deliver these therapies.

Ultimately, to get generative AI in healthcare right we need input from the clinicians who will use these tools – and who understand the ramifications of applying AI without first rigorously testing applications to ensure they are safe and provide clear clinical value.

Senior care executives have the privilege and responsibility to embrace the profound changes brought about by resident advocacy. We can champion a new era of senior care that puts the individual at the center, honoring their unique identity and aspirations.